Just reported
From Stryker's results release of 29 października 2026; its quarterly report has since been filed.
Actual
6,52B USD
+7,6% y/y
-1,0% q/q
Guided
—
No guide given
Actual
1,96 USD
-12% y/y
-41% q/q
Guided
—
No guide given
Actual
1,03B USD
-8,9% y/y
-38% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →The themes Stryker is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Udziały w przychodach to szacunki za nine months ended 2026-09-30, a nie dane z raportu złożonego do regulatora.
Surgical instruments and navigation systems
Powered surgical tools and navigation equipment that help surgeons carry out procedures.
Endoscopy and communications equipment
Cameras and related equipment that let clinicians view inside the body, alongside systems that connect operating-room equipment.
Patient and emergency-care equipment
Hospital beds, patient-handling equipment, emergency monitors and defibrillators, intensive-care disposables, and clinician communication systems.
Minimally invasive vascular devices
Catheters and other devices used in minimally invasive treatment of stroke and venous blood clots.
Brain and cranial surgery products
Products for brain and open-skull surgery, including synthetic bone grafts and products used to treat spinal bone conditions.
Joint and trauma implants and robotic surgery systems
Hip, knee, shoulder, ankle and trauma implants, plus robotic systems and surgical tools used in these operations.
Pełne sprawozdania finansowe →
Stryker makes equipment used during operations and in hospital wards, including cameras, surgical instruments, beds, emergency devices and systems that help hospital staff communicate. It also makes minimally invasive devices to treat strokes and blood clots, plus implants and robotic systems used in joint replacement and trauma surgery. It sells mainly to doctors, hospitals and other healthcare facilities, both directly and through distributors.
Zbudowane z własnych raportów spółki Stryker Corp. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
309,64 USD-0,9%zamknięcie 13 lis
Dane do 30 września 2026, z raportu 10-Q złożonego 30 października 2026
Stryker sells operating-room and hospital-care equipment and minimally invasive stroke and clot-treatment devices to hospitals and clinicians, alongside implants and robots for joint surgery.
Grade A+
Pasek pod ceną pokazuje ocenę w każdym dniu, wyliczoną wyłącznie z dokumentów, które były wtedy już publiczne.
Pokazujemy 2 z 41 kwartałów historii ocen spółki Stryker Corp.. Pozostałe 39 sięgają do październik 2016.